Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
LOUISVILLE, Kentucky – – Alcon takes over development of POT-4 as a treatment for patients with age-related macular degeneration – Deal provides path for Alcon to acquire Potentia Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with [...]
